"It is very positive that we are now broadening the use of our GMP facility and our expertise to process development and production of other advanced drugs, so-called ATMPs (Advanced Therapy Medicinal Products). In the collaboration with Region Östergötland, we will use our experience in manufacturing ATMPs, to provide cell-based investigational drugs for clinical studies for an external customer, which brings revenues to Xintela. The availability of approved GMP facilities for ATMP manufacturing in Sweden is very low and it feels extra important that we can contribute to the supply of investigational drugs to patients where the medical need is very high", says Liselotte Theorell, Xintela Director Quality Management, QP.

"Region Östergötland and the Burn Center, Linköping University Hospital are very positive about a collaboration with Xintela and look forward to seeing the first Swedish ATMP (cell-based) product for the treatment of severe burns as a result of this collaboration. This can be a major step forward for the development of new treatment methods in the field of burn care and regenerative medicine in Sweden", says Consultant and Associate professor Moustafa Elmasry, Head of Research and Development Unit for skin and cultured cells, Department of Hand and Plastic surgery, Linköping University Hospital.